• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

黄体生成素对前列腺癌甾体生成途径的影响。

Effect of luteinizing hormone on the steroidogenic pathway in prostate cancer.

机构信息

University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA.

出版信息

Prostate. 2011 Jun 1;71(8):892-8. doi: 10.1002/pros.21305. Epub 2010 Nov 17.

DOI:10.1002/pros.21305
PMID:21456071
Abstract

BACKGROUND

Recent data has shown that prostate cancer (PCA) cells are capable of producing testosterone directly from cholesterol, which may contribute to the development of castration resistance. While up-regulation of steroidogenic enzymes has been previously described during castration-resistant prostate cancer (CRPC) progression, regulation of this process is poorly defined. These data examine the role of luteinizing hormone (LH) in the regulation of steroidogenic machinery in PCA cells.

METHODS

PCA cell lines LNCaP, C4-2B, and 22RV1 were exposed to LH. Gene expression was quantified using real-time PCR and protein expression was characterized with standard Western blot analysis. Steroid analysis was performed using radioimmunoassay (RIA). Cell viability was measured using an MTS viability assay.

RESULTS

Androgen-sensitive (LNCaP) and -independent PCA cells (C4-2B and 22RV1) express both mRNA and protein for LH and LH receptor (LHR). Exposure of these cells to LH for 4 hr increased the expression of several steroidogenic genes. Exposure for 10 days resulted in the increase of additional genes. At both time points, the upregulation of these genes was dose-dependent. This was mirrored by an increase in the expression of several key steroidogenic enzymes, including StAR, CYB5B, CYP11A, and 3βHSD. LH stimulated the production of progesterone and testosterone in LNCaP cells as measured by RIA. We have also demonstrated that treatment of LNCaP cells with LH enhanced their viability.

CONCLUSIONS

Our data show that LH-mediated activation of LHR significantly up-regulates the expression of genes and enzymes required for steroidogenesis and increases steroid production in PCA cells.

摘要

背景

最近的数据表明,前列腺癌 (PCA) 细胞能够直接从胆固醇中产生睾酮,这可能有助于去势抵抗的发展。虽然在去势抵抗性前列腺癌 (CRPC) 进展过程中已经描述了甾体生成酶的上调,但对这一过程的调控知之甚少。这些数据研究了促黄体生成素 (LH) 在调节 PCA 细胞甾体生成机制中的作用。

方法

将 PCA 细胞系 LNCaP、C4-2B 和 22RV1 暴露于 LH 中。使用实时 PCR 定量基因表达,并用标准 Western blot 分析来描述蛋白表达。使用放射免疫测定 (RIA) 进行类固醇分析。使用 MTS 活力测定法测量细胞活力。

结果

雄激素敏感 (LNCaP) 和非依赖雄激素的 PCA 细胞 (C4-2B 和 22RV1) 均表达 LH 和 LH 受体 (LHR) 的 mRNA 和蛋白。将这些细胞暴露于 LH 4 小时可增加几种甾体生成基因的表达。暴露 10 天可导致更多基因的增加。在这两个时间点,这些基因的上调都是剂量依赖性的。这与几种关键甾体生成酶(包括 StAR、CYB5B、CYP11A 和 3βHSD)的表达增加相吻合。LH 通过 RIA 刺激 LNCaP 细胞产生孕激素和睾酮。我们还证明,用 LH 处理 LNCaP 细胞可增强其活力。

结论

我们的数据表明,LH 介导的 LHR 激活显著上调了甾体生成所需的基因和酶的表达,并增加了 PCA 细胞中的类固醇生成。

相似文献

1
Effect of luteinizing hormone on the steroidogenic pathway in prostate cancer.黄体生成素对前列腺癌甾体生成途径的影响。
Prostate. 2011 Jun 1;71(8):892-8. doi: 10.1002/pros.21305. Epub 2010 Nov 17.
2
Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.利用新型异种移植模型鉴定 EP4 作为治疗去势抵抗性前列腺癌的潜在靶点。
Cancer Res. 2010 Feb 15;70(4):1606-15. doi: 10.1158/0008-5472.CAN-09-2984. Epub 2010 Feb 9.
3
Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line.丙戊酸可诱导人前列腺癌细胞系发生神经内分泌分化并上调UGT2B7的表达。
Drug Metab Dispos. 2007 Jun;35(6):968-72. doi: 10.1124/dmd.107.014662. Epub 2007 Mar 19.
4
Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.威尔姆斯肿瘤抑制基因WT1对雄激素信号通路的转录调控。
Anticancer Res. 2001 Jan-Feb;21(1A):1-10.
5
Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance.花生四烯酸激活肿瘤内甾体合成在前列腺癌向去势抵抗性进展过程中。
Prostate. 2010 Feb 15;70(3):239-51. doi: 10.1002/pros.21057.
6
Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model.胆固醇调节的改变有助于在小鼠异种移植模型中向去势抵抗性前列腺癌进展过程中产生肿瘤内雄激素。
Prostate. 2010 Mar 1;70(4):390-400. doi: 10.1002/pros.21072.
7
Characterisation of steroid receptor expression in the human prostate carcinoma cell line 22RV1 and quantification of androgen effects on mRNA regulation of prostate-specific genes.人前列腺癌细胞系22RV1中类固醇受体表达的特征分析及雄激素对前列腺特异性基因mRNA调控作用的定量分析。
J Steroid Biochem Mol Biol. 2004 Oct;92(3):187-97. doi: 10.1016/j.jsbmb.2004.07.004.
8
Regulation of endometrial cancer cell growth by luteinizing hormone (LH) and follicle stimulating hormone (FSH).黄体生成素(LH)和卵泡刺激素(FSH)对子宫内膜癌细胞生长的调节作用。
Br J Cancer. 2000 Dec;83(12):1730-4. doi: 10.1054/bjoc.2000.1507.
9
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.在去势抵抗性前列腺癌进展过程中,雄激素水平通过肿瘤内从头类固醇生成而升高。
Cancer Res. 2008 Aug 1;68(15):6407-15. doi: 10.1158/0008-5472.CAN-07-5997.
10
Sex steroid hormone metabolism and prostate cancer.性甾体激素代谢与前列腺癌
J Steroid Biochem Mol Biol. 2004 Nov;92(4):281-6. doi: 10.1016/j.jsbmb.2004.10.004. Epub 2004 Dec 19.

引用本文的文献

1
LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial.化疗初治、醋酸阿比特龙联合泼尼松治疗的 mCRPC 患者中使用 LH-RH 拮抗剂保留治疗:随机 II 期 SPARE 试验的结果。
Prostate Cancer Prostatic Dis. 2022 Apr;25(4):778-784. doi: 10.1038/s41391-022-00533-6. Epub 2022 Apr 16.
2
A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer.去势抵抗性前列腺癌潜在病理生理机制综述
Res Rep Urol. 2021 Jun 30;13:457-472. doi: 10.2147/RRU.S264722. eCollection 2021.
3
Transgenic mice overexpressing the LH receptor in the female reproductive system spontaneously develop endometrial tumour masses.
转基因雌性生殖系统过度表达 LH 受体的小鼠会自发形成子宫内膜肿瘤团块。
Sci Rep. 2021 Apr 23;11(1):8847. doi: 10.1038/s41598-021-87492-5.
4
Novel functions of the luteinizing hormone/chorionic gonadotropin receptor in prostate cancer cells and patients.黄体生成素/绒毛膜促性腺激素受体在前列腺癌细胞和患者中的新功能。
PLoS One. 2020 Sep 3;15(9):e0238814. doi: 10.1371/journal.pone.0238814. eCollection 2020.
5
Luteinizing Hormone Levels Relate to the Unfavorable Pathology of Prostate Cancer.促黄体生成素水平与前列腺癌的不良病理相关。
J Clin Med. 2020 Apr 29;9(5):1281. doi: 10.3390/jcm9051281.
6
Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting.在化疗初治的转移性去势抵抗性前列腺癌患者中使用恩杂鲁胺:一项真实世界环境下的韩国多中心回顾性研究。
Investig Clin Urol. 2020 Jan;61(1):19-27. doi: 10.4111/icu.2020.61.1.19. Epub 2019 Dec 10.
7
Modulation of AKR1C2 by curcumin decreases testosterone production in prostate cancer.姜黄素对AKR1C2的调节作用可降低前列腺癌中的睾酮生成。
Cancer Sci. 2018 Apr;109(4):1230-1238. doi: 10.1111/cas.13517. Epub 2018 Feb 19.
8
Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial.醋酸阿比特龙联合促性腺激素释放激素(LHRH)疗法与醋酸阿比特龙单药疗法对比研究:在未经化疗、转移性且病情进展的去势抵抗性前列腺癌患者中保留LHRH疗法(SPARE):一项随机对照试验的研究方案
Trials. 2017 Oct 4;18(1):457. doi: 10.1186/s13063-017-2195-x.
9
Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy.游离睾酮水平在接受二线治疗的转移性去势抵抗性前列腺癌患者中的作用。
Oncol Lett. 2017 Jan;13(1):22-28. doi: 10.3892/ol.2016.5392. Epub 2016 Nov 17.
10
Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial.促黄体生成素释放激素激动剂在降低前列腺癌男性睾酮水平方面优于包膜下睾丸切除术:一项随机临床试验的结果
J Urol. 2017 Jun;197(6):1441-1447. doi: 10.1016/j.juro.2016.12.003. Epub 2016 Dec 9.